Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae announces new leadership structure to drive global growth

Invitae announces new leadership structure to drive global growth

January 09, 2017

Sean George appointed as chief executive officer, Randy Scott to become executive chairman

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, Ph.D., its co-founder and current president and chief operating officer, has been named chief executive officer for the company. Current chairman and chief executive officer Randy Scott will become executive chairman of the board of directors and remain full time at the company. The appointments are effective immediately.

“Sean ...

Read more


Invitae meets annual volume guidance, projects doubling of volume in 2017, accelerates Genome Network by acquiring scalable patient-centered data company

Invitae meets annual volume guidance, projects doubling of volume in 2017, accelerates Genome Network by acquiring scalable patient-centered data company

January 06, 2017

Grew volume 200% by delivering approximately 57,000 billable reports for the full year 2016 and approximately 20,000 billable reports in Q4, generating positive gross margins

 Added multiple new regional payers, securing coverage for more than 175 million covered lives

Announced new biopharma partnership and acquired patient-centered data company AltaVoice to expand the Invitae Genome Network to include both genetic information and patient-centered data

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced initial fourth ...

Read more


Invitae acquires patient-centered data company AltaVoice, creating new offerings to advance research and access to care for patients with inherited and rare diseases

Invitae acquires patient-centered data company AltaVoice, creating new offerings to advance research and access to care for patients with inherited and rare diseases

January 06, 2017

Acquisition will enable more comprehensive understanding of inherited diseases through permission-based sharing of genetic information and patient insights

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced it has acquired AltaVoice (formerly PatientCrossroads), a privately owned, patient-centered data company with a global platform for collecting, curating, coordinating, and delivering safeguarded data from patients and clinicians. The acquisition, complemented by several other unique partnerships, expands Invitae’s Genome Network, designed to connect patients, clinicians, advocacy organizations ...

Read more


Invitae to present at the 35th Annual J.P. Morgan Healthcare Conference

Invitae to present at the 35th Annual J.P. Morgan Healthcare Conference

December 28, 2016

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that members of the company’s management team will present at the 35th Annual J.P. Morgan Healthcare conference on Wednesday, January 11, 2017 at 2:30 p.m. Pacific at The Westin St. Francis in San Francisco.

The live, listen-only webcast of both the presentation and breakout session immediately following may be accessed by visiting the investors section of the company’s website at ir ...

Read more


Invitae announces major expansion of its pediatric, neurological, and rare disease genetic test offerings

Invitae announces major expansion of its pediatric, neurological, and rare disease genetic test offerings

December 21, 2016

New and expanded panels allow clinicians to screen for genetic changes associated with epilepsy, developmental disorders, and a variety of other pediatric, neurological, and rare conditions

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the availability of 24 new and 19 expanded genetic test panels, allowing clinicians to gain information on 183 new genes with clinical and diagnostic significance. This launch represents a significant expansion of the company’s pediatric, neurological, and rare disease offerings, which include tests ...

Read more


Invitae sees increase in utilization of its inherited prostate cancer genetic tests

Invitae sees increase in utilization of its inherited prostate cancer genetic tests

December 14, 2016

High quality, comprehensive, affordable genetic tests designed to ensure access for prostate cancer patients who may benefit from broader panel testing, including BRCA1, BRCA2, and other genes associated with prostate cancer

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has seen a significant increase in genetic testing for prostate cancer since the publication of landmark data showing testing may be underutilized when screening for and treating the second most common cancer in men. The company’s ...

Read more


Invitae and TME Research announce landmark new study to evaluate universal genetic testing of breast cancer patients

Invitae and TME Research announce landmark new study to evaluate universal genetic testing of breast cancer patients

December 08, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, and TME Research, LLC today announced the initiation of a new clinical collaboration to evaluate the benefits of universal genetic testing of breast cancer patients. TME Research represents more than 300 breast care practices around the country whose core mission is to improve the quality and access to targeted breast cancer care.

The collaboration, called the Universal Breast Cancer Genetic Testing Registry, will enroll 1,000 breast cancer patients across 20-25 TME ...

Read more


Invitae adds two genes, offers faster turnaround time for its Breast Cancer STAT Panel

Invitae adds two genes, offers faster turnaround time for its Breast Cancer STAT Panel

December 07, 2016

Now providing a faster and more comprehensive panel for patients with breast cancer who need rapid test results to guide surgical decisions

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the expansion of its Breast Cancer STAT Panel with the addition of two important breast cancer predisposition genes – ATM and CHEK2 – and a faster turnaround time (TAT) with results available in as few as five days at no additional cost. The announcement was made at the San Antonio ...

Read more


Invitae to present at the Canaccord Genuity Medical Technology & Diagnostics Forum

Invitae to present at the Canaccord Genuity Medical Technology & Diagnostics Forum

November 17, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that members of the company’s management team will present at the Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 17, 2016 at approximately 3:00 p.m. Eastern at the Westin Grand Central in New York City.

The live, listen-only webcast of the presentation may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcast will be ...

Read more


Invitae Announces Pricing of Public Offering of Common Stock

Invitae Announces Pricing of Public Offering of Common Stock

November 17, 2016

Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,333,333 shares of its common stock at a price to the public of $6.00 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $44 million. The offering is expected to close on or about November 22, 2016 ...

Read more

Invitae’s Mission

Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice in order to improve healthcare for billions of people. There are three stages to Invitae’s business model:

  1. Make genetic testing more affordable and accessible than ever before.
  2. Build a secure and trusted genome management infrastructure with which we help individuals manage their own genetic information over the course of their life.
  3. Design a genome network, a global community for sharing genetic information to advance science and medicine and allow patients, doctors and organizations to connect around genetic conditions.

Invitae’s four core principles

  1. Patients should own and control their own genetic information.
  2. Healthcare professionals are fundamental in ordering and interpreting genetic information.
  3. Driving down the price of genetic information will increase that information’s clinical and personal utility.
  4. Genetic information is more valuable when shared.

About Invitae

Invitae Corporation’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas.

For more information, visit out website at ir.invitae.com and follow us on Twitter: @invitae and @invitaeIR